Bringing a cell or gene therapy from clinical promise to commercial reality requires more than breakthrough science. It requires an organization that is ready to operate differently. Commercialization depends on aligning strategy, operations, technology, quality, manufacturing, supply chain, and cross-functional teams around an executable path forward.

This is where I work.

I help cell and gene therapy organizations translate commercialization strategy into the operating capabilities required to launch, scale, and reliably deliver innovative therapies to patients.

For more than 20 years, I have led complex initiatives across life sciences, healthcare, and technology — partnering with executives and cross-functional teams to bring clarity to complexity, create alignment, and turn strategy into execution.

My work spans commercialization readiness, operating model and capability development, technology enablement, cross-functional transformation, operational excellence, and strategic program leadership.

I am often brought in when the destination is understood but the path is not yet clear — when priorities compete, capabilities are still developing, and critical decisions and dependencies need to come together into a practical roadmap.

I bring both strategic perspective and hands-on operating experience. I can work with executives to frame the problem and make the decisions, then work with the organization to translate those decisions into capabilities, plans, and execution.

Today, I work with life sciences leaders navigating consequential moments of growth, transformation, and commercialization.

My focus is helping organizations understand and build what is required to turn promising therapies into sustainable commercial operations — and ultimately reach the patients they are intended to serve.